Theravance Biopharma TBPH
NASDAQ TBPH
$17.03 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Theravance Biopharma (TBPH) Research & Development (2013 - 2026)

Updated

Theravance Biopharma's Research & Development came in at $4.71 million for Q2 2026, down 55.1% from $10.49 million a year earlier and down 19.2% from the prior quarter.

Analysis

Theravance Biopharma (TBPH) Research & Development (2013 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Theravance Biopharma reported Research & Development of $26.01 million, down 36.0% year-over-year; for FY2025, it was $37.41 million, down 0.6% from FY2024.

  • Research & Development has declined in each of the last five years, with a five-year compound annual growth rate of -32.2% (FY2020 to FY2025).
  • Going back by year, Research & Development was $37.64 million in FY2024 (-7.3%), $40.62 million in FY2023 (-35.9%), $63.39 million in FY2022 (-67.3%) and $193.66 million in FY2021 (-25.8%).
  • The Q2 2026 figure represents the lowest quarterly Research & Development in data going back to Q1 2013.
  • Year-over-year, Research & Development has declined for four consecutive quarters, with an average decline of 10.1% over the last eight quarters.
  • The fastest year-over-year change in Research & Development over five years came in Q1 2025 (growth of 27.7%), and the weakest in Q3 2022 (a decline of 77.4%).
  • Business Quant data shows TBPH's Research & Development at $5.83 million (Q1 2026), $7.36 million (Q4 2025) and $8.11 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Theravance Biopharma 883.70 Mn -543.66 Mn - 4.71 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.71 Mn
Mar 31, 2026 5.83 Mn
Dec 31, 2025 7.36 Mn
Sep 30, 2025 8.11 Mn
Jun 30, 2025 10.49 Mn
Mar 31, 2025 11.45 Mn
Dec 31, 2024 9.45 Mn
Sep 30, 2024 9.27 Mn
Jun 30, 2024 9.95 Mn
Mar 31, 2024 8.97 Mn
Dec 31, 2023 8.31 Mn
Sep 30, 2023 8.31 Mn
Jun 30, 2023 9.43 Mn
Mar 31, 2023 14.57 Mn
Dec 31, 2022 15.35 Mn
Sep 30, 2022 9.87 Mn
Jun 30, 2022 14.92 Mn
Mar 31, 2022 23.25 Mn
Dec 31, 2021 31.23 Mn
Sep 30, 2021 43.74 Mn
API Access

Theravance Biopharma Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=TBPH&period=max&api_key=YOUR_API_KEY